Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119677 · ClinicalTrials.gov registry record · Phase 1
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT01119677 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 120 participants.
The verdict
NCT01119677, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether titration of Avonex reduces the severity of flu-like symptoms (FLS). Secondary objectives of this study are to determine whether titration of Avonex reduces the incidence of FLS and to evaluate the overall safety and tolerability of Avonex intramuscular (IM) injections.
Interventions
- DRUG Avonex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-05-05 |
| Est. Completion | 2010-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119677
The ClinicalTrials.gov registry entry for NCT01119677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avonex is the first listed.
NCT01119677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119677 about?
NCT01119677 is a clinical study titled "A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers". The primary objective of the study is to determine whether titration of Avonex reduces the severity of flu-like symptoms (FLS). Secondary objectives of this study are to determine whether titration of Avonex reduces the incidence of FLS and to evaluate the overall safety and tolerability of Avonex i...
What is the current status of trial NCT01119677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2010-05-05. Estimated completion is 2010-10-23.
What interventions are being tested in trial NCT01119677?
The interventions under investigation include: Avonex (DRUG).
Who is sponsoring clinical trial NCT01119677?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.